Table 2.
Statistical analysis using a repeated measures 2- or 3-way analysis of variance of remifentanil during acquisition of opioid intravenous self-administration, where data are presented in Figure 2.
| Figure 2 | F (DFn, DFd) | P | ||
|---|---|---|---|---|
| Remifentanil IVSA | ||||
| Day 1 | Cumulative reinforcers | Time | F (1.385, 40.17) = 40.52 | P < 0.0001**** |
| Pain | F (1, 29) = 3.117 | P = 0.0880 | ||
| Time × pain | F (120, 3480) = 1.838 | P < 0.0001**** | ||
| AUC | Pain | F (1, 27) = 2.902 | P = 0.1000 | |
| Sex | F (1, 27) = 1.711 | P = 0.2019 | ||
| Interaction | F (1, 27) = 0.1663 | P = 0.6866 | ||
| Day 2 | Cumulative reinforcers | Time | F (120, 3480) = 69.37 | P < 0.0001**** |
| Pain | F (1, 29) = 4.377 | P = 0.0453* | ||
| Time × pain | F (120, 3480) = 2.447 | P < 0.0001**** | ||
| AUC | Pain | F (1, 27) = 5.155 | P = 0.0314* | |
| Sex | F (1, 27) = 3.51 | P = 0.0718 | ||
| Interaction | F (1, 27) = 4.41 | P = 0.0451* | ||
| Day 3 | Cumulative reinforcers | Time | F (2.151, 62.39) = 107.1 | P < 0.0001**** |
| Pain | F (1, 29) = 2.865 | P = 0.1013 | ||
| Time × pain | F (120, 3480) = 1.383 | P = 0.0042** | ||
| AUC | Pain | F (1, 27) = 3.498 | P = 0.0723 | |
| Sex | F (1, 27) = 1.006 | P = 0.3249 | ||
| Interaction | F (1, 27) = 1.417 | P = 0.2443 | ||
| Day 4 | Cumulative reinforcers | Time | F (2.340, 67.86) = 81.03 | P < 0.0001**** |
| Pain | F (1, 29) = 1.252 | P = 0.2723 | ||
| Time × pain | F (120, 3480) = 1.065 | P = 0.3005 | ||
| AUC | Pain | F (1, 27) = 0.2393 | P = 0.6287 | |
| Sex | F (1, 27) = 0.9762 | P = 0.3319 | ||
| Interaction | F (1, 27) = 0.2393 | P = 0.6287 | ||
| Day 5 | Cumulative reinforcers | Time | F (2.185, 63.36) = 119.9 | P < 0.0001**** |
| Pain | F (1, 29) = 2.476 | P = 0.1264 | ||
| Time × pain | F (120, 3480) = 0.7456 | P = 0.9819 | ||
| AUC | Pain | F (1, 27) = 0.2233 | P = 0.6403 | |
| Sex | F (1, 27) = 0.004630 | P = 0.9462 | ||
| Interaction | F (1, 27) = 0.2233 | P = 0.6403 | ||
| Figure 1C | Cumulative reinforcers by day and sex | Male day 1 | t = 2.000, df = 8 | P = 0.0805 |
| Male day 2 | t = 3.015, df = 8 | P = 0.0167* | ||
| Male day 3 | t = 2.639, df = 8 | P = 0.0297* | ||
| Male day 4 | t = 0.3926, df = 8 | P = 0.7049 | ||
| Male day 5 | t = 1.168, df = 8 | P = 0.2763 | ||
| Female day 1 | t = 1.155, df = 6 | P = 0.2919 | ||
| Female day 2 | t = 0.4681, df = 6 | P = 0.6563 | ||
| Female day 3 | t = 0.6504, df = 6 | P = 0.5395 | ||
| Female day 4 | t = 1.223, df = 6 | P = 0.2673 | ||
| Female day 5 | t = 1.641, df = 6 | P = 0.1519 |
A 1-sample t test and Wilcoxon test were used for the cumulative reinforcers being different than theoretical value of zero in panel c. P values are provided for each of the factors (time, pain, and appropriate interactions) for active and inactive nose pokes, and number of reinforcers earned. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
AUC, area under the curve; IVSA, intravenous self-administration.